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Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced in preg-
nancy by the developing embryo after conception and later by the syncytiotrophoblast
to prevent disintegration of the corpus luteum of the ovary. hCG also plays a role in cellu-
lar differentiation/proliferation and may activate apoptosis (1). hCG is extensively used
as a parenteral fertility medication in lieu of luteinizing hormone.
hCG is composed of 244 amino acids with a molecular mass of 36.7 kDa. It is hetero-
dimeric, with a (alpha) and b (beta) subunits creating a small hydrophobic core. The vast
majority of the outer amino acids are hydrophilic.
hCG has been radiolabeled mostly with 125I for various applications, such as kinetic
studies of hCG conformations (2), thermodynamic analysis of hCG monoclonal antibodi-
es (3), structure-activity studies (4) and placental protein synthesis studies (5).
421
Acta Pharm. 59 (2009) 421–429 Original research paper
10.2478/v10007-009-0035-6









1Nuclear Medicine Research Group




Science and Research Branch





Accepted Semptember 8, 2009
b-Human chorionic gonadotropin (b-hCG) was successi-
vely labeled with [67Ga]-gallium chloride after conjuga-
tion with freshly prepared diethylenetriaminepentaacetic
acid dianhydride (ccDTPA). After solid phase purification
of the radiolabeled hormone, high performance liquid
chromatography showed radiochemical purity higher
than 95 % under optimized conditions (specific activity
= 22–23 TBq mM–1, labeling efficiency 80 %). Preliminary
in vivo studies (ID g–1, %) in male wild-type rats showed
marked gonadal uptake of the tracer after 240 minutes in
agreement with the biodistribution studies and reported
b-hCG receptors. Target to blood ratios were 5.1 and 15.2
after 3 and 24 hours, respectively, while target to muscle
ratios were 35 and 40 after 3 and 24 hours, respectively.
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hCG receptors (hCGRs) are mainly located on the gonads, and also on many other
tissues including female and male breasts (6). hCGR is also widely overexpressed in vari-
ous neoplasmic cells (7), human colon malignancies (8), ovarian, endometrial, and uter-
ine cervix cancers (9), and 20–40 % of all common epithelial carcinomas (10).
It is used in the development of targeting agents for cancer therapy (11) and has
been shown to be highly effective in targeting and destroying prostate and breast cancer
cell metastases in vitro (12). hCGR has been also used in targeted delivery of superpa-
ramagnetic iron oxide nanoparticles for MRI studies of metastatic breast cancer cells in
peripheral tissues (13) and as a conjugated form with doxorubicin (14).
According to our knowledge, there are no reports of radiolabeled hCG hormone
and its truncates for imaging studies in the literature. In this work, following the prepa-
ration of an hCG conjugate for diagnostic hCGR studies using metallic positron emis-
sion tomography (PET) or single photon computed tomography (SPECT) radioisotopes,
67Ga-labeled hCG was prepared for preliminary biodistribution studies, based on our re-
cent experience of the preparation of radiometal-labeled proteins (15).
A precise labeling strategy was employed using freshly-prepared diethylenetriamine-
-pentaacetic dianhydride (ccDTPA), at various hCG concentrations and gallium-67 for




Production of 67Ga was performed at the Agricultural, Medical and Industrial Re-
search School (AMIRS, Karaj, Iran) using a 30 MeV cyclotron (Cyclone-30, IBA, Belgium).
Enriched zinc-68 chloride with > 95 % enrichment was obtained from the Ion Beam Sepa-
ration Department at AMIRS. All chemicals were purchased from commercial sources.
Pregnyl™, (b-hCG), is a pharmaceutical sample purchased form Daro-Pakhsh Co., Iran
(1500 IU) and was used without further purification. Cyclic DTPA dianhydride was freshly
prepared and kept under a blanket of N2. Paper chromatography (PC) was performed
by counting Whatman No. 2 paper (Whatman, UK) using a thin layer chromatography
scanner, Bioscan AR2000, Bioscan Europe Ltd. (France). To determine the specific activity,
analytical HPLC was performed using a Shimadzu LC-10AT (Japan) instrument, armed
with two detector systems, flow scintillation analyzer (Packard-150 TR) and UV-visible
detector (Shimadzu), and Whatman Partisphere C-18 column (250 ´ 4.6 mm), Whatman,
USA. Solid phase purification of the radiolabeled hormone was performed using C18
Sep-Pak from Waters Co. (USA). Calculations were based on the 184 keV peak for 67Ga.
All values were expressed as mean ± standard deviation and the data were compared
using Student’s t-test.
Animal studies were performed in accordance with the United Kingdom Biological
Council’s Guidelines on the Use of Living Animals in Scientific Investigations, 1987. Ap-
proval of the AMIRS Ethical Committee was obtained for this research.
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The wild-type rats (NMRI) were purchased from the Pasteur Institute of Iran, Karaj,
all weighing 180–200 g and were acclimatized at proper rodent diet and 12h/12h
day/night cycle.
Percentage of the injected dose in tissue (ID g–1, %) was determined using a high
purity germanium (HPGe) detector coupled with a CanberraTM (model GC1020-7500SL,
USA) multichannel analyzer based on the area under the curve for 184 keV photopeak
and the calculated counting system efficiency.
Procedures
Production of 67Ga – 68Zn(p,2n)67Ga was used as the best nuclear reaction for the pro-
duction of 67Ga. Impurities could be removed in the radiochemical separation process.
After the target bombardment process, chemical separation was carried out in the no-
-carrier-added form. The irradiated target was dissolved in 10 mol L–1 HCl (15 mL) and
the solution was passed through a cation-exchange resin (AG 50W, H+ form 37–74 mm),
which had been pre-conditioned by passing 9 mol L–1 HCl. The column was then washed
with 25 mL of 9 mol L–1 HCl at a rate of 1 mL min–1 to remove copper and zinc ions. To
the eluent, 30 mL water plus about 100 mL of 6 mol L–1 HCl solution was added. The lat-
ter solution was loaded on another exchange resin (AG1X8 Cl– form, 74–149 mm)
pretreated with 6 mol L–1 HCl (100 mL). Finally, gallium-67 was eluted as [67Ga]GaCl3
using 2 mol L–1 HCl (50 mL); the whole process took about 60 min.
Radionuclide purity control. – Gamma spectroscopy of the final sample was carried
out by counting in a high purity germanium detector coupled to a CanberraTM multi-
-channel analyzer for 1000 seconds.
Chemical purity control. – The presence of zinc and copper cations was checked by
polarography. The area under the curve of the polarogram of test samples was lower
than that of the standards even at 1 mg mL–1 of standard zinc and copper.
Conjugation of ccDTPA with human recombinant hCG. – The chelator ccDTPA was con-
jugated to the hCG using slightly modified cyclic anhydride method (16). Conjugation
was performed at a 1:1 molar ratio. In brief, 20 mL of a 1 mg mL–1 suspension of ccDTPA
in dry chloroform (Merck, Germany) was pipetted under ultrasonication and transferred
to a glass tube. The chloroform was evaporated under a gentle stream of nitrogen. Com-
mercially available hCG (1500 IU, 1 mL, pH 8, » 3 nmol) (17) was subsequently added
and gently mixed at room temperature for 60 min.
Radiolabeling of hCG conjugate with 67Ga. – The hCG conjugate was labeled using an
optimized protocol according to the literature (18). Typically, 74 MBq of 67Ga-chloride
(in 0.2 mol L–1 HCl) was added to a conical vial and dried under a nitrogen flow. To the
67Ga containing vial, the conjugated fraction was added in 1 mL of phosphate buffer (0.1
mol L–1, pH 8) and mixed gently for 30 seconds. The resulting solution was incubated at
room temperature for 30 minutes. Following incubation, the radiolabeled hCG conjugate
was checked using PC methods for purity. In case of the presence of unreacted amounts
of impurities, the sample can be purified by solid phase extraction using C18 Sep-Pak.
Briefly, the column was pretreated with absolute ethanol and water, respectively, fol-
lowed by injection of the radiolabeling mixture. The column was left at room tempera-
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ture for 5 min and was then washed with water fractions until the flow-through activity
in each fraction was less than 10 mCi. Finally, the radiolabeled compound was eluted from
the column using 1 mL-fractions of citrate buffer (pH 5.5). Control labeling experiments
were also performed using 67GaCl3, and ccDTPA with 67GaCl3.
Quality control of [67Ga]-hCG. – A 5-mL sample of the final fraction was spotted on a
chromatography paper (Whatman No. 1, Whatman), and developed in a mixture of 1
mol L–1 ccDTPA in H2O as the mobile phase.
High performance liquid chromatography. – HPLC was performed on the final prepara-
tion using reverse stationary phase. Acetate buffer solution (50 mmol L–1 pH 5.5) was
eluent A and citrate buffer solution was B (50 mmol L–1, pH 4) (flow rate 1 mL min–1) for
20 min in order to elute low molecular mass components. Radiolabeled peptide was
eluted using the following gradients: 100 % A, 0 % B 5 min, 70 % A, 30 % B 5 min, 50 %
A, 50 % B 5 min, 0 % A, 100 % B 5 min.
Stability testing of the radiolabeled compound. – Stability of 67Ga-DTPA-hCG in the phos-
phate buffer solution was determined by storing the final solution at 4 °C for 4 hours
and performing frequent PC analyses to determine radiochemical purity. PC analysis of
the conjugated product was also performed to monitor degradation products or other
impurities after the conjugated DTPA-hCG was stored at –20 °C for more than 1 month.
After subsequent 67Ga-labelling of the stored conjugated product, both the labeling effi-
ciency and radiochemical purity were determined.
Stability testing of the radiolabeled compound in the presence of serum. – Labeled com-
pound stability in serum was assessed by gel filtration on a Sepharose column. The col-
umn was equilibrated with PBS and eluted with PBS at a flow rate of 0.5 mL min–1 at
room temperature; 0.5 mL fractions were collected.
Biodistribution of 67Ga-DTPA-hCG in wild-type rats. – To determine its biodistribution,
67Ga-DTPA-hCG was administered to wild-type rats. A volume (50 mL) of final 67Ga-
-DTPA-hCG solution containing 40 ± 2 mCi radioactivity was injected intravenously to
rats through tail veins. The animals were sacrificed at exact time intervals (0.25, 0.5, 1, 2,
3 and 24 h). The specific activity of different organs was calculated as percentage of the
area under the curve of 184 keV peak per gram using an HPGe detector.
RESULTS AND DISCUSSION
The labeling yield of 67Ga-DTPA-hCG has been studied in a wide range of hCG/
DTPA ratios in order to optimize the process and to improve 67Ga-DTPA-hCG perfor-
mance in vitro. The overall radiolabeling efficiency was over 80 %. Because of its iso-
electric point (IEP) of around 4, hCG is soluble in physiological serum pH (5.5–7) being
adequately stable (19). However, its structural integrity is strongly dependent on the disul-
phide bonds, and its reduction completely destroys the structure; thus, the radiolabeling
strategies based on redox reactions cannot be employed.
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Regarding the peptide sequence for hCG for alpha and beta subunits, the existence
of 6 lysine moieties in the alpha subunit and 4 in the beta subunit, can load to NH2-me-
diated conjugation through ccDTPA acylation.
The eluted fractions were checked for the presence of radioactivity in order to deter-
mine the 67Ga-DTPA-hCG containing fractions. The fraction with maximum radioactiv-
ity was chosen as the suitable final product for quality control and that with appropriate
specific activity for animal tests. The radiolabeling reached 95 % after 60 min.
For better radiochemical purity, solid-phase extraction using a C18 column was used.
The radiolabeled mixture was loaded on the pre-conditioned Sep-Pak Columm. Eluting
the loaded column with water removed free 67Ga3+ as well as 67Ga-DTPA due to their
ionic properties. After purging the column with nitrogen for 5 minutes, the radiolabeled
protein was eluted using citrate buffer in the first 3 elutions. At this stage, the buffer
eluted fraction with the highest activity was tested by HPLC in order to determine its
radiochemical purity before administration to wild-type rats for biodistribution studies.
Fig. 1a shows the HPLC chromatogram of 67Ga3+. The fast eluting component (2.79 min)
was shown to be a mixture of free 67Ga and 67Ga-DTPA which was washed out on the
reverse phase stationary phase. The radiolabeled protein was washed out in 14.78 minu-
tes (Fig. 1b).
It has been already shown that the median in vivo and in vitro biopotency for hCG is
approximately 13000 IU mg–1, with a range from 8360 to 16800 IU mg–1 (22). Thus, con-
sidering the used (74 MBq) and the radiochemical purity of the final purified sample
(95 %), a specific activity of 22–23 TBq mmol–1 was obtained after Sep-Pak purification.
Stability of the radiolabeled protein in vitro was determined after challenge with
phosphate-buffered saline and serum. PC analysis showed that the proteins retained the
radiolabel over a period of 1 hour in final solution.
These results were confirmed by gel filtration chromatography. After incubation of
[67Ga]-DTPA-hCG with PBS for 2 h there was no change in the Rf for [67Ga]-DTPA-hCG
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Fig. 1. HPLC chromatogram of: a) free 67GaCl3 solution, b) of solid phase purified final radiolabeled
solution, on a reversed phase column using a gradient of acetate/citrate buffer.
and there was no evidence of any large-scale release of free Ga resulting in the appear-
ance of a new radiopeak. Similarly, gel filtration chromatography of [67Ga]-DTPA-hCG
after a 2-h incubation with human serum showed that the radioactivity still eluted in the
same fraction. Thus, there was no evidence of either degradation or transchelation of
67Ga to other serum proteins over a time period.
The distribution of free 67GaCl3 in appropriate buffer has been already reported
elsewhere (21) Fig. 2 demonstrates the biodistribution of [67Ga]-DTPA-hCG among tis-
sues in male wild-type rats. A volume (0.1 mL) of final [67Ga]-DTPA-hCG solution con-
taining 40 mCi of radioactivity was injected into the dorsal tail vein. The total amount of
radioactivity injected into each rat was determined by measuring the 1-mL syringe be-
fore and after injection in a dose calibrator with fixed geometry.
The animals were sacrificed by ether asyxphycation at selected times after injection
(0.25 h to 2 h), the tissues (blood, heart, spleen, kidneys, liver, intestine, muscle, bone,
brain, stomach, lung, skin, pancreas, bladder and testes) were weighed and their specific
activities were determined with a g-ray scintillation detector as percent of the area under
the curve of 184 keV per gram of tissue.
The radiolabeled hormone is gradually removed from the circulation and possible
serum protein binding exists for this hormone. Most non-glycosylated proteins mainly
possess hepatic accumulation, while due to the existence of residual sugar moieties on
the hCG structure (leading to more solubility) liver uptake is not significant in this case.
Skin, muscle, brain pancreas and also kidney demonstrated low uptake; however,
spleen demonstrated high uptake. Up to 120 minutes the testes showed low uptake while
after 240 minutes 16 % of the tracer accumulated in the testes.
hCG transport in rat testicular microvasculature has been already studied by elec-
tron microscopy and by analyzing the transfer of the radiolabeled hormone. It has been
observed that the same receptor molecule which is present in target Leydig cells is also
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Fig. 2. Biodistribution of [67Ga]-DTPA-hCG (1.85 MBq, 40 mCi) in wild-type rats 0.25–24 h after i.v.
injection via tail vein. (ID g–1 (%) – percentage of injected dose per gram of tissue based on the area
under the curve of 184 keV peak in gamma spectrum.
involved in transcytosis through the endothelial cells (22). The hormone can be internali-
zed by coated pits and vesicles on the luminal side of the endothelium. It was then locali-
zed in the endosomal compartment and subsequently appeared to be delivered by smooth
vesicles into the subendothelial space.
hCG receptors are widely expressed in gonadal cells; however, the presence of these
receptors was also detected in several other non-gonadal female and male tissues. The ex-
pression level of non-gonadal hCG receptors is much lower than in the gonads, although
their expression is regulated by similar mechanisms and observed in malignancies (20).
For better comparison, the target/blood and target/muscle ratios were determined
from ID g–1 (%) curves to demonstrate the time dependence of specific uptake in the tar-
get organ. The significance of uptake in gonadal tissue was observed at least 3 hours after
administration of the tracer in both cases. However, the hCG hormone partly remained
in serum binding species while after 24 hours major accumulation with the lowest back-
ground was in the testes (Fig. 3).
CONCLUSIONS
Total labeling and formulation of [67Ga]-DTPA-HCG took about 60 minutes. A suit-
able specific activity product was formed via insertion of 67Ga cation. No other labeled
conjugates were observed upon PC and/or HPLC analysis of the final preparations. The
radio-labeled complex was stable in human serum for at least 2 hours and no significant
amount of free 67Ga or 67Ga-DTPA was observed. A 95 % radiochemical purity was de-
tected by HPLC. The final preparation was administered to wild-type rats and biodis-
tribution of the radiopharmaceutical was checked 0.25 to 24 hours later. In 2–3 hours,
the radiolabeled hormone was cleared from the blood circle and most of the tracer accu-
mulated in spleen. After 3–24 h, major tracer uptake was observed in the testes. Target/
muscle ratio after 24 h reached 40, demonstrating specific accumulation on the hCGR
positive tissues. [67Ga]-DTPA-hCG can be a suitable probe for biodistribution of hCGR
in various physiological and malignant diseases with over-expressed hCGRs.
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Fig. 3. a) Target/blood and b) target/muscle ratios for [67Ga]-DTPA-hCG 0.25–24 h after adminis-
tration.
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S A @ E T A K
Razvoj radiomarkiranog -humanog koriogonadotropina
AMIR R. JALILIAN, MOHAMMAD REZA KHOSHDEL, JAVAD GAROUSI, HASSAN YOUSEFNIA,
MOHAMMAD A. HOSSEINI, SAEED RAJABIFAR i DARYOUSH SARDARI
b-humani korionski gonadotropin (b-hCG) uspje{no je markiran s [67Ga] galijevim
kloridom nakon konjugacije sa svje`e prire|enim dianhidridom dietilentriaminpentaocte-
ne kiseline (ccDTPA). Nakon ~i{}enja radiomarkiranog hormona na ~vrstoj fazi, radioke-
mijska ~isto}a bila je prema HPLC ve}a od 95 % (specifi~na aktivnost = 22–23 TBq mM–1,
u~inkovitost markiranja 80 %). Preliminarni in vivo pokusi (ID g–1, %) na mu`jacima div-
ljeg tipa {takora pokazali su da obilje`eni hormon zna~ajno ulazi u gonade nakon 240
minuta, {to je u suglasnosti s ispitivanjima biodistribucije i podacima o receptorima za
b-hCG. Omjer koncentracija u gonadama i krvi bio je 5,1, odnosno 15,2 nakon 3, odnosno
24 sata, dok je omjer koncentracija u gonadama i mi{i}ima bio 35, odnosno 40 nakon 3,
odnosno 24 sata.
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